On October 7, 2026 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") reported a BioTuesdays feature examining the Company’s strategy to address the critical treatment gap of maintaining disease control after first-line chemotherapy for metastatic pancreatic cancer. The article features an interview with AIM Chief Executive Officer Thomas K. Equels and explores the scientific and clinical foundation supporting Ampligen’s (rintatolimod) potential as a pancreatic cancer maintenance therapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The feature examines Ampligen’s potential to convert the immunosuppressive tumor microenvironment, turning "cold" tumors into a more immunologically active state and thus enabling checkpoint inhibitors to work more effectively. This approach is being evaluated in a clinical trial of Ampligen in combination with AstraZeneca’s Imfinzi (durvalumab) following first-line chemotherapy (the "DURIPANC" trial). With final Ampligen dosing complete, AIM is working toward the next stage of clinical development as it awaits the reporting of primary and secondary endpoints.
"For patients with metastatic pancreatic cancer, extending survival and improving quality of life are the outcomes that matter most," said AIM Chief Executive Officer Thomas K. Equels. "The BioTuesdays feature captures why we are pursuing Ampligen in this setting: the urgent need for an effective maintenance therapy and the potential to address the immune resistance that makes pancreatic cancer so difficult to treat. With Ampligen dosing complete, our focus is on translating the anticipated clinical findings and biomarker research into a path toward pivotal development. Our mission is to give patients more time, better quality of life and hope."
BioTuesdays also examines encouraging survival and quality-of-life observations from AIM’s Netherlands-approved Named Patient Program, which provided Ampligen to patients with pancreatic cancer following FOLFIRINOX. Exploratory analyses identified patient subgroups with favorable survival observations based on immune and tumor biomarkers. The segment also highlights observations from a Dutch Named Patient Program (NPP) in which patients with radiologically stable pancreatic cancer after FOLFIRINOX received Ampligen as a maintenance treatment. In an exploratory analysis of 39 patients with a neutrophil-to-lymphocyte ratio ("NLR") below 4.5, median overall survival was 34.8 months, measured from the start of FOLFIRINOX. This encouraging observation supports further investigation of Ampligen following chemotherapy. These findings are informing AIM’s efforts to better understand patient response and guide future trial design. The Named Patient Program was not a controlled clinical trial, and comparisons with historical controls do not establish treatment efficacy.
The article brings together the clinical observations, mechanism of action and biomarker research underpinning AIM’s pancreatic cancer strategy. It also discusses the Company’s patents covering Ampligen in combination with checkpoint inhibitors, pancreatic cancer orphan drug designations in the United States and European Union, and potential financing or pharmaceutical partnership pathways to support a pivotal Phase 3 study.
(Press release, AIM ImmunoTech, OCT 7, 2026, View Source [SID1234673253])